Tuberculosis in the blood
By analyzing the chemicals in the blood, scientists can find out who develops active tuberculosis
Although a quarter of the world population is infected with the pathogen that causes tuberculosis, only about ten percent develop the disease during their lifetime. An international team of scientists, including some from the Max Planck Institute for Infection Biology in Berlin showed that the amounts of certain chemical compounds which circulate in the blood, change prior to the onset of the disease even months before a clinical diagnosis can be made. In future, this may allow to predict tuberculosis based on a blood screening – a highly valuable progress in the fight against this life threatening disease.
Tuberculosis remains a major threat to humankind: each year, over 1.5 millions die of this disease, making the responsible microbe – Mycobacterium tuberculosis – the deathliest one on Earth. Even though some risk factors are known – such as smoking – it is largely unclear who will develop the disease.
To fight tuberculosis successfully, an early diagnosis is extremely important. Earlier work of scientists from Max Planck Institute for Infection Biology revealed that tuberculosis patients can be identified based on a number of chemical compounds in blood. Their analysis showed that a number of amino acids have lower concentrations in the blood of tuberculosis patients than of the healthy individuals, while some important signaling molecules – such as kynurenin or cortisol – are present at higher concentrations.
Disease prediction from blood samples
This study was performed by a consortium supported by the Grand Challenges program of the Bill and Melinda Gates Foundation. The team tested whether these and other molecules could be helpful to predict progression to tuberculosis in apparently healthy individuals. To this end, they recruited some 4,500 individuals from four African countries and followed them up for several years. During the study, around 100 individuals were diagnosed with active tuberculosis. Then, hundreds of chemical compounds were analyzed in blood samples taken from the recruited individuals. “We were able to predict who will develop tuberculosis in future. Furthermore, we were identified risk factors, such as molecules characteristic for smokers, who are at a higher risk for developing the disease” – so January Weiner from Max Planck Institute for Infection Biology.
The scientists validated their findings using independent data sets and thereby showed that the chemical compounds characteristic for progressors – those, who will develop tuberculosis at a later time point – are largely similar to the chemical compounds which allow distinguishing tuberculosis patients from healthy individuals. Moreover, the findings are specific to tuberculosis and the profiles of patients suffering from other respiratory diseases were different.
In future, these results may be the starting point for a rapid and inexpensive prognostic test. According to Stefan H.E. Kaufmann, director at the Max Planck Institute for Infection Biology in Berlin, “this type of screening can be used at a very early stage in suspected tuberculosis cases and will allow preventive therapy prior to disease onset. This would be an important step forward in fight against tuberculosis”.